BIIB093 for Brain Bruise (ASTRAL Trial)

"BIIB093 was first tested in 2009 at the Texas Diabetes Institute. 18,375 clinical trials related to this treatment have been conducted since then, with 6 currently recruiting patients primarily from Marietta, Georgia."

"Affirmative. Clinicaltrials.gov displays that this research project, which was first made available on October 6th 2019, is recruiting participants at the current moment in time. 160 volunteers must be found from 16 distinct medical sites."

"This medical trial is currently recruiting 160 individuals with brain contusions ranging in age from 18 to 85. In order to be eligible, participants must possess a clinical diagnosis of brain contusion and show lesions on non-contrast computed tomography scans totalling more than 3 mL per the Investigator's assessment. Additionally, they must have a Glasgow Coma Scale score between 5 and 15 upon screening as well as display functional independence prior to sustaining their index head injury."

"BIIB093 has been trialled in 207 cities across 25 nations. This drug, backed by Amylin Pharmaceuticals LLC., was initially tested in 2009 with the participation of 521 individuals. Following its Phase 4 completion, 18375 additional studies have since concluded."

"As indicated by the requirements for this experiment, only those over 18 and below 85 are eligible to participate."

"This medical trial is being held in 16 different locations, including Marietta, Boston and Dallas. To reduce the strain of participation, it's best to select a clinic near you for enrollment."

"To carry out this medical study, Biogen requires 160 eligible patients spread between the Research Facility in Marietta, Georgia and Research Site in Boston, Massachusetts."

"Our experts at Power have judged the safety of BIIB093 to be a 2 out of 3, as this is only in its Phase 2 clinical trial; while there is some evidence backing up its safety there still needs to be data collected proving efficacy."